Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Werewolf Therapeutics, Inc.HOWL · Entity 7244 | Chief Operating Officer | January 03, 2023 | January 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Werewolf Therapeutics, Inc.
Report date January 03, 2023 · Filed January 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2032-12-31 | Direct | 93,600 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 93,600 · Balance 93,600 F1: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 10, 2023 02:34 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 93,600 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001404 · doc4.xml · derivative · entry 1 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,600 Underlying: Common Stock · 93,600 shares Expires 2032-12-31 F1 · derivative.exercise_date: The option was granted on January 3, 2023 with a Vesting Commencement Date of January 1, 2023. The shares underlying the option vest in equal monthly installments over four years, commencing on the date that is one month following the Vesting Commencement Date and vesting monthly thereafter through January 1, 2027. Read SEC document |
| January 06, 2022 Filed Jan 18, 2022 23:33 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (Right to Buy) · Derivative | 70,967 | $0.00 Strike: $11.55 | $0.00 |
DisclosureSEC source: 0000899243-22-002206 · doc4.xml · derivative · entry 1 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,967 Underlying: Common Stock · 70,967 shares Expires 2032-01-05 F1 · derivative.exercise_date: The option was granted on January 6, 2022 with a Vesting Commencement Date of January 1, 2022. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through January 1, 2026. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 21:26 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,102 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0000899243-22-000510 · doc4.xml · derivative · entry 3 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,034 Underlying: Common Stock · 14,102 shares Expires 2030-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on May 20, 2020 with a Vesting Commencement Date of June 1, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on the first anniversary of the Vesting Commencement Date and 2.0833% of the shares vesting each month thereafter through June 1, 2024. Read SEC document |
| December 30, 2021 Filed Jan 4, 2022 21:26 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | Exercise / conversionCommon Stock | 14,102 | $1.56 | $21,999.12 |
DisclosureSEC source: 0000899243-22-000510 · doc4.xml · nonDerivative · entry 1 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:17 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | SaleCommon Stock | 135 | $13.97 | $1,886.44 |
DisclosureSEC source: 0000899243-21-048768 · doc4.xml · nonDerivative · entry 2 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Leonard Revocable Living Trust Disclosed balance after: 122,157 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.93 to $13.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) of this Form 4. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:17 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | SaleCommon Stock | 2,865 | $13.39 | $38,355.19 |
DisclosureSEC source: 0000899243-21-048768 · doc4.xml · nonDerivative · entry 1 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Leonard Revocable Living Trust Disclosed balance after: 122,292 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.84 to $13.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) of this Form 4. Read SEC document |
| April 30, 2021 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 27,311 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-21-018117 · doc4.xml · derivative · entry 2 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,311 Underlying: Common Stock · 27,311 shares Expires 2031-04-29 F2 · derivative.exercise_date: The option was granted on April 30, 2021. The shares underlying the option vest over four years in equal monthly installments through April 30, 2025. Read SEC document |
| December 08, 2020 Filed May 4, 2021 20:31 UTC | Werewolf Therapeutics, Inc. HOWL · Entity 7244 | GrantStock Option (right to buy) · Derivative | 99,163 | $0.00 Strike: $4.77 | $0.00 |
DisclosureSEC source: 0000899243-21-018117 · doc4.xml · derivative · entry 1 Leonard Reid · CIK 0001857795 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,163 Underlying: Common Stock · 99,163 shares Expires 2030-12-07 F1 · derivative.exercise_date: The option was granted on December 8, 2020. 25% of the shares underlying the options vest on December 8, 2021, the remaining shares vest in equal monthly installments through December 8, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.